Watch APVO. Know when insiders buy.
One email the day a filing lands. Free.
APVO
Aptevo Therapeutics Inc.
1.60
−0.01 −0.93%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$26.4MNET CASH $9.8M52W 1.60 – 28.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.4M | −$6.4M | — | -5.31 | −$5.5M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$6.8M | −$6.7M | — | -6.41 | −$8M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$6M | −$5.8M | — | -75.85 | −$5.2M | — | — | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$7.6M | −$7.5M | — | -2.23 | −$6.7M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$6.2M | −$6.2M | — | -151.29 | −$7.1M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$6.5M | −$6.4M | — | -1581.81 | −$6.6M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.4M | −$6.3M | — | -27750.47 | −$5.8M | — | — | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$5.2M | −$5.1M | — | -357.86 | −$5.2M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$6M | −$5.9M | — | -1236.96 | −$6.2M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$7M | −$6.8M | — | -368.21 | −$6.7M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.4M | −$5.9M | — | -2260.61 | −$5.3M | — | — | Feb 14 |
| Q3 2023 · Sep 30 | — | — | — | −$6.6M | −$6.3M | — | -22.16 | −$6.2M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$26.3M | −$26M | — | -87.27 | −$25.6M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$24.6M | −$24.1M | — | -31460.23 | −$23.8M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$28.9M | −$17.4M | — | -2316.83 | −$11.7M | — | — | — | — |
| FY2022 · to Dec 31 | $3.1M | — | −$28.6M | $8M | 257.8% | 1.57 | −$21M | $29K | −$21.1M | — | — |
| FY2021 · to Dec 31 | $12.3M | — | −$21.4M | −$28.5M | -231.5% | -6.07 | −$21.7M | $713K | −$22.4M | — | — |
| FY2020 · to Dec 31 | $4.3M | — | −$27.5M | −$17.8M | -411.9% | -5.23 | −$29.3M | $88K | −$29.4M | — | — |
Every number comes from Aptevo Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.